Novo Nordisk Phase 3 Alzheimer's GLP-1 Strategy 2020

Novo Nordisk announced its decision to advance into phase 3 development for early Alzheimer's disease treatment and provided an update on GLP-1 research and development strategy. The conference outlined the company's 2025 strategic aspirations including expanded innovation in diabetes, obesity treatment portfolio leadership, and entry into serious chronic diseases including cardiovascular disease, NASH, and chronic kidney disease.